6 results
The study will investigate the safety and efficacy of emicizumab in patients with hemophilia A with inhibitors against FVIII.
The main objective of this treatment protocol is to study the efficacy on the treatment response after adding a single gift of Mylotarg. Furthermore, monitoring of toxicity and long term efficacy is also important.
This study will evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of emicizumab in patients of all ages with mild (FVIII level between > 5% and < 40%) or moderate hemophilia A (FVIII level between >= 1% and…
to develop and explore measuring methods using conventional smartphones to quantify fatigue, disease activity, and short term and long progression in a day-to-day setting in patients with MS. Key research questions: - Are the NeuroKeys and MS Sherpa…
Study MO41787 will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of emicizumab administered at 3 mg/kg Q2W for a period of 52 weeks in previously untreated patients (PUPs) and minimally treated patients (MTPs) at study…
Primary objectiveTo determine whether individualized pharmacokinetic (PK)-guided dosing of emicizumab is non-inferior to conventional dosing of emicizumab in the - proportion of patients without treated bleeds (6 months before and after intervention…